A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Summary

This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.

Timeline

Start

2026-01-10

Primary completion

2027-12-02

Completion

2028-06-02

Drugs

Indications